Investors

Positioned to deliver…

Seasoned management team and Board with extensive experience in R&D, manufacturing and commercialisation within the life sciences sector. 

In-house and external regulatory specialists supporting CE mark, WHO PQ and FDA 510(k) market clearance. 

IS0 13485: 2016 


Comprehensive proprietary IP portfolio  

Transformational point-of-care molecular diagnostic platform 

Long-standing, validating relationships with key advisers and partners


Strong product pipeline: respiratory panel, HPV, STIs  


 

 

Overview

QuantuMDx is an ambitious UK-based life science tools and diagnostics company. We have developed a highly innovative, portable molecular diagnostic platform, Q-POC™ which offers rapid, sample to answer, multiplexed testing within 30 minutes, at the point of care. 


Find out more

News

Our announcements, achievements and latest news

QuantuMDx partners with Cignpost Diagnostics

Providing a rapid, PCR COVID-19 testing solution to the UK film & TV industry NEWCASTLE UPON TYNE, UK, 16 August 2021. QuantuMDx has announced it is partnering with Cignpost Diagnostics, (‘Cignpost’), a leading provider of COVID-19 workplace testing to the film and TV industry. Cignpost has installed QuantuMDx’ portable Q-POC™ system onto a filming location within the UK, providing rapid, onsite PCR testing for cast and crew members, to ensure a safe working environment thus allowing filming to progress without interruption…

Read More

QuantuMDx launches Q-POC™ – rapid, PCR point of care diagnostic system

NEWCASTLE UPON TYNE, UK: QuantuMDx today announces the launch of Q-POC™ – a rapid, PCR point of care diagnostic system.…

Read More

QuantuMDx included on PHE National Microbiology Framework

Diagnostic Goods and Services (Lot 1) Research and Development Goods (Lot 2) NEWCASTLE UPON TYNE, UK, 08 June 2021. QuantuMDx has…

Read More

QuantuMDx appoints Mirre de Noo as Non-Executive Director

NEWCASTLE UPON TYNE, UK, 26 May 2021. QuantuMDx has appointed Mirre de Noo, as a Non-Executive Director. Mirre has over…

Read More